Posted by Michael Wonder on 21 Jun 2021
Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis
18 June 2021 - Novartis’ Cosentyx has been recommended by NICE for the treatment of adults with non-radiographic axial spondyloarthritis.
NICE has recommended Cosentyx (secukinumab) as an option for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation that is not controlled well enough with non-steroidal anti-inflammatory drugs in adults.
